Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83 ... are available in more than 180 countries worldwide. Consumer Health Company (Opella) (Sold-Out entity) Headquartered in France ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Sanofi, France's biggest pharmaceutical group, said last week that it was in talks with CD&R for the sale of a 50% controlling stake in Opella, triggering criticism from government opponents over the ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... rising income levels and greater health and well-being awareness, Sanofi ...

Sanofi and CD&R enter exclusive talks to sell a 50% stake in Opella, Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra ...

PAI Partners increased its offer for Sanofi’s consumer health division by 200 million euros. CD&R remains the frontrunner for a 50% stake in Sanofi’s Opella, despite PAI's late bid.

Sanofi could announce the deal with buyout firm CD&R as soon as early next week, according to the people. The consumer health unit, known as Opella, is set to be valued at around €15 billion ...

(Bloomberg) -- Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail ...